TABLE 1.
Antibacterial antibodies | Disease | Target | Advantages | Disadvantages |
---|---|---|---|---|
Anthim (obiltoxaximab) | Pulmonary anthrax | Toxin |
Easy to use Specific diagnosis Low toxicity No damage to microbiota |
High cost Low variety |
Raxibacumab | Anthrax | Toxin | ||
Zinplava (bezlotoxumab) | Clostridium difficile infections | C. difficile toxin B | ||
Actozumab | C. difficile infections | C. difficile toxin A | ||
Edobacumab | Escherichia coli infections | Lipid A | ||
Nebacumab | E. coli infections | Lipid A | ||
Aurograb | Staphylococcus aureus infections | Grfa (lipoprotein) |